ASN's Mission

ASN leads the fight to prevent, treat, and cure kidney diseases throughout the world by educating health professionals and scientists, advancing research and innovation, communicating new knowledge, and advocating for the highest quality care for patients.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005


The Latest on Twitter

Kidney Week

Abstract: SA-OR040

The Pro-Fibrotic Serum Marker MMP7 Predicts Accelerated GFR Loss in the General Population

Session Information

  • Biomarkers in CKD
    November 09, 2019 | Location: 152, Walter E. Washington Convention Center
    Abstract Time: 04:54 PM - 05:06 PM

Category: CKD (Non-Dialysis)

  • 2101 CKD (Non-Dialysis): Epidemiology, Risk Factors, and Prevention


  • Enoksen, Inger Therese Tonsberg, The Arctic University of Norway, UiT, Tromsø, Norway
  • Svistounov, Dmitri, The Arctic University of Norway, UiT, Tromsø, Norway
  • Norvik, Jon V., University Hospital of North Norway, Tromsø, Norway
  • Solbu, Marit D., The Arctic University of Norway, UiT, Tromsø, Norway
  • Eriksen, Bjorn Odvar, The Arctic University of Norway, UiT, Tromsø, Norway
  • Melsom, Toralf, The Arctic University of Norway, UiT, Tromsø, Norway

Group or Team Name

  • Metabolic and Renal Research Group, UiT The Arctic University of Norway

Age related loss of glomerular filtration rate (GFR) is a major contributor to the global chronic kidney disease (CKD) epidemic. CKD is associated with increased morbidity and mortality and there is a need for novel biomarkers that identify at risk persons at an early stage to delay or prevent CKD onset. Matrix Metalloproteinase (MMP) 2 and 7 are key players in interstitial remodeling and mediate renal fibrosis development in animal models. We investigated whether serum MMP2, MMP7 and their inhibitor TIMP1, were associated with accelerated age-related GFR decline and incident CKD in middle-aged individuals from the general population.


In the Renal Iohexol Clearance Survey (RENIS) we performed GFR measurements (using iohexol clearance) in 1627 subjects, aged 50-62 years, from the general population without self-reported diabetes, kidney or cardiovascular disease. 1324 (81%) had follow-up measurements after a median of 5.6 years. The biomarkers were analyzed in baseline serum samples with a Bioplex 200 machine. Using multiple logistic regression analysis, we evaluated the risk of accelerated GFR decline (defined as subjects with the 10% steepest GFR slope) and incident CKD (defined as GFR <60ml/min/1.73m2).


After adjustment for age, sex, baseline GFR and urinary albumin-creatinine ratio (ACR), higher levels of MMP7 were associated with an increased risk of accelerated GFR decline (Odds ratio (95% confidence interval)) per one SD increase in MMP7: 1.68 (1.39-2.04) and incident CKD: 1.71 (1.25-2.34). The results were attenuated, but remained significant in the fully adjusted model (1.48 (1.20-1.81) and 1.53 (1.08-2.18)). Prediction of accelerated GFR decline improved after addition of MMP7 to a model with age, sex, baseline GFR and ACR (aera under the ROC curve increased from 0.72 to 0.75 (p=0.054), continuous net reclassification improvement: 0.34 CI: 0.16-0.52). Similar results were obtained using alternative definitions of accelerated GFR decline such as ≤-3.0 ml/min/1.73m2/year or a GFR decline rate twice the cohort mean (≤-1.68 ml/min/1.73m2/year). MMP2 and TIMP1 showed no association with GFR decline.


The pro-fibrotic biomarker MMP7 was independently associated with increased risk of accelerated GFR decline and incident CKD in middle-aged persons from the general population.


  • Government Support - Non-U.S.